EMPAVELI (pegcetacoplan) is the first approved treatment for C3G or primary IC-MPGN for patients 12 years and older in Canada Approval supported by Phase 3 52-week VALIANT study demonstrated reduced ...

Most of us think of cars as a huge purchase. A reliable new vehicle can cost anywhere from $25,000 to $32,000. But what if a single dose of medicine costs even more than that? That's exactly the ...

The company's asset-to-be has two commercialized medicines on the market based on the same active ingredient.

Bringing together Biogen and Apellis’ commercialization capabilities will maximize the potential of both EMPAVELI ® and SYFOVRE ®, while Apellis’ talent and expertise will accelerate Biogen’s entry ...

The MarketWatch News Department was not involved in the creation of this content. Exton, PA, March 05, 2026 (GLOBE NEWSWIRE) -- Spherix Global Insights today announces the release of its latest Market ...

Paroxysmal nocturnal hemoglobinuria (PNH) – the rare blood disorder characterized by premature destruction of red blood cells – found itself in the spotlight, as did shares of Omeros Corp.

Paroxysmal nocturnal hemoglobinuria (PNH) – the rare blood disorder characterized by premature destruction of red blood cells – found itself in the spotlight, as did shares of Omeros Corp.

Diagnosed at a young age with a rare and potentially life-threatening disease, one man learned the power of taking control. When South Carolinian Roger was diagnosed with paroxysmal nocturnal ...

Atropos Health, a real-world data company, announced a partnership with pharmaceutical giant Novartis to help identify individuals with the rare disease paroxysmal nocturnal hemoglobinuria (PNH) who ...

Healio spoke with Marcel P. Devetten, MD, associate professor of oncology and hematology at University of Nebraska Medical Center, about multidisciplinary care in paroxysmal nocturnal hemoglobinuria ...